Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexion Pharmaceuticals, Inc.
Alexion’s Soliris eculizumab Receives Marketing Approval in Canada for All Patients with PNH
February 13th, 2009
Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Soliris® (eculizumab) for the treatment of all patients in Canada with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Canada for the treatment of PNH. “Soliris has had a life-changing impact on patients with PNH and represents the only effective and safe drug therapy available for their disease,” said Dr. Loree M. Larratt, M.D., Department of Medicine, Divisional Director...
Source: Health Business Week (2009-02-13)
|
